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Serological Biomarkers of Tissue Turnover Identify
Responders to Anti-TNF Therapy in Crohn’s Disease:
A Pilot Study
Wouter T. van Haaften, MD, PhD1,2, Joachim H. Mortensen, PhD, MSc3, Anders K. Dige, MD, PhD4, Henning Grønbæk, MD, PhD4,
Christian L. Hvas, MD, PhD4, Anne-Christine Bay-Jensen, PhD3, Morten A. Karsdal, PhD3, Peter Olinga, PhD2, TinaManon-Jensen, PhD3
and Gerard Dijkstra, MD, PhD1
INTRODUCTION: Anti–tumor necrosis factor (TNF) therapy is effective in inducing remission in Crohn’s disease in 60%of
patients. No serological biomarkers are available, which can predict response to anti-TNF.We aimed to
investigate serological markers of collagen turnover reflecting tissue inflammation as predictors of
response to anti-TNF.
METHODS: In 2 retrospective observational cohorts, markers for matrix metalloproteinase–degraded type III and IV
collagens (C3MandC4M, respectively) and for formation of type III and IV collagens (PRO-C3andPRO-C4,
respectively)weremeasured in serumandcomparedwith standardC-reactiveprotein inpatientswith active
Crohn’s disease who started infliximab (IFX, n5 21) or adalimumab (ADA, n5 21). Disease activity was
classified by the Harvey-Bradshaw index (active disease ‡5); response was defined as clinical remission.
RESULTS: Seventeen patients (81%) treated with IFX were in remission at week 14; 15 patients (71%) treated with
ADAwere in remission at week8. SerumC4Mat baselinewas increased in nonresponders comparedwith
responders (IFX: 35.062.4 vs23.262.6,P50.04, ADA: 53.063.2 vs34.162.8,P50.006). C4M
levels at baseline predicted response in both cohorts (IFX: odds ratio 39 [95% confidence interval,
2.4–523.9] P5 0.02, cutoff 35.2 nmol/L; ADA: odds ratio 26 [95% confidence interval, 1.8–332.5],
P5 0.01, cutoff 46.9 nmol/L). C-reactive protein was not able to predict response to anti-TNF.
DISCUSSION: Response to anti-TNF therapy within the first 14weeks of treatment can be predicted based on baseline
levels of basementmembranemarkerC4M.Thismarker couldbeused asbiomarker for response to anti-
TNF and could aid in early therapy decisionmaking. Validation in larger well-defined cohorts is needed.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A372
Clinical and Translational Gastroenterology 2020;11:e00217. https://doi.org/10.14309/ctg.0000000000000217
INTRODUCTION
Anti–tumor necrosis factor (anti-TNF) agents such as infliximab
(IFX) and adalimumab (ADA) are effective in inducing and
maintaining clinical and endoscopic remission in luminal and
fistulizing Crohn’s disease (CD) (1–6). Up to 30% of patients with
CD who start anti-TNF have no or insufficient response after 14
weeks of treatment, and there are no available biomarkers, which
can predict primary nonresponse (7). As new medical therapeutic
options such as anti–integrin a4b7 (vedolizumab) or anti–
interleukin (IL)-12 and IL-23 (ustekinumab) have become avail-
able for patients with CD, the need for biomarkers that predict
treatment response increases (8). Also, increasing evidence
suggests that early ileocecal resection innonstricturingCDcould be
considered a reasonable alternative to IFX therapy (9). Biomarkers
that predict the response to anti-TNF may help in the decision to
switch class of therapy or to recommend surgery (9).
C-reactive protein (CRP), a valuable biomarker of disease ac-
tivity in CD, can discriminate between responders and nonre-
sponders to anti-TNF, but conflicting results are reported (10–13).
CRP, which is almost exclusively excreted by hepatocytes as part of
the acute-phase response on stimulation by IL-1 and IL-6 and by
TNF originating from the site of inflammation, is a relatively in-
direct inflammatory marker as it is not produced in the organ in
which the inflammation takes place (10,14). Instead, biomarkers
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that are produced at the site of inflammation may be superior in
predicting response to anti-TNF.
A disturbed balance in the remodeling of extracellular matrix
(ECM) contributes to the pathophysiology of CD (15). Matrix
metalloproteinases (MMPs) are collagenases, which are upregu-
lated on inflammation in active CD (16). These enzymes are
produced at the site of inflammation by inflammatory cells such
as macrophages and T cells (15). As shown previously, levels of
MMP-9–degraded type III collagen (C3M) are elevated in pa-
tients with CD with active inflammation (defined as CPR $5)
compared to CD without active inflammation (defined as CRP
,5) and to healthy controls (16,17). Type IV collagen is the most
abundant collagen of the basementmembrane. Epithelial damage
on inflammation leads to an increase in permeability of the in-
testinal basement membrane, which is largely restored on IFX
therapy (18,19). Markers of MMP-mediated degradation of type
III (C3M) (20) and IV (C4M) collagens (21) might be superior in
predicting response to anti-TNF compared with CRP.
Several studies reported increased mucosal and submucosal fi-
brosis in ileocecal resection specimens from patients with CD who
required surgery following IFX treatment failure compared with pa-
tients whowere IFX naive and underwent primary ileocecal resection
(22,23). Increased messenger RNA (mRNA) expression of procolla-
gen peptidases has been associated with primary IFX nonresponse
(23). Therefore, formation products of type III (PRO-C3) (24) and
type IV(PRO-C4) (25) collagensmight alsobe suitablebiomarkers for
early detection of patients who do not respond to anti-TNF.
In this pilot study, we aimed to provide a proof of concept by
showing that biomarkers of ECM turnover can predict response
to anti-TNF within the first 8 to 14 weeks of anti-TNF treatment.
MATERIALS AND METHODS
Study design and population IFX (Groningen) and ADA
(Aarhus) cohort
This retrospective observational pilot study was designed to com-
pare serum levels of collagen formation and degradation markers
between responders vs nonresponders to anti-TNF in 2 in-
dependent cohorts of patients with CD, starting IFX (Groningen,
the Netherlands) and ADA (Aarhus, Denmark) remission in-
duction therapy. Sera from patients with biopsy-confirmed CD
who started IFX induction therapy between November 2009 and
March 2016 (Remicade, Janssen Biologics B.V., Leiden, Holland;
intravenous infusions of 5mg/kg bodyweight) were collected from
the database of the inflammatory bowel disease (IBD) center of the
University Medical Center Groningen, the Netherlands (UMCG,
single center,Table 1). Blood sampleswere collectedbefore patients
received the infusion at baseline and 2, 6, and 14 weeks after
treatment was initiated. After retrieval, samples were centrifuged
for 10 minutes (2000g at room temperature), pipetted in 0.5 mL
cryovials, and stored at 280 °C until further analysis. Harvey-
Bradshaw index (HBI) scores were collected from baseline and at
week 14. Sera from patients with biopsy-confirmed CD who re-
ceived ADA induction therapy between January 2009 andOctober
2012 (Humira; Abbott, Chicago, IL; subcutaneous injections of 160
mgat baseline, 80mgatweek 2, and then40mgeveryweekor every
other week) were collected at the Department of Hepatology and
Gastroenterology at Aarhus University Hospital, Denmark (single
center, Table 1) (26). Blood samples were collected before patients
received the infusion at baseline and 1 and 8 weeks after treatment
was initiated. After retrieval, samples were centrifuged for 10 mi-
nutes (300g at 20 °C), pipetted in 1.5 mL cryovials, and stored
at 280 °C until further analysis. HBI scores were documented at
baseline and at week 8.
Inclusion criteria were patientswith active disease (HBI$5) at
baseline receiving either IFX or ADA for at least 14 weeks (27).
Exclusion criteria were (i) no HBI available, (ii) resection due to
intra-abdominal stenosis or fistulae, (iii) autoimmune and/or fi-
brotic diseases not (related to) CD, (iv) any kind of cancer, except
skin cancer or hematologic cancer, (v) any kind of (also non–CD
related) surgery or balloon dilatation within 6 months before a
serum sample was taken or during the induction phase, and (vi)
solely perianal disease indication for starting IFX (Figure 1).
Disease activity was based on HBI (active disease: HBI $5).
Clinical response was defined as anHBI,5 (remission) at week 8
(ADA cohort) or at week 14 (IFX cohort).
Biomarker assays
Neoepitope fragments of ECM synthesis and degradation were
assessed by solid-phase competitive enzyme-linked immuno-
sorbent assays (ELISAs). The markers included in this study are
markers for MMP-degraded type III and IV collagens (C3M and
C4M, respectively) and formation of type III and IV collagens
(PRO-C3 and PRO-C4, respectively).
Ninety-six-well plates precoated with streptavidin (Roche Di-
agnostic cat. No. 11940279, Hvidovre, Denmark) were coated with a
biotinylated antigen against the biomarker for 30 minutes at room
temperature. All samples were diluted in incubation buffer containing
1% bovine serum albumin (Sigma-Aldrich, cat. No. a-7906,$98 pu-
rity). Samples and controls were incubated in the antigen and strep-
tavidin precoated plates with horseradish peroxidase–conjugated
monoclonal antibodies for 1–3 hours at 4 °C/20 °C or for 20 hours at
4 °C with agitation at 300 rpm, according to the manufacturer’s pro-
tocols. Subsequently, tetramethylbenzidine (Kem-En-Tec cat. No.
438OH,Taastrup,Denmark)wasadded(100mL/well), andplateswere
incubated for15minutes at roomtemperature andagitatedat 300 rpm.
Stopping buffer (1% H2SO4) was added to stop the tetramethylbenzi-
dine reaction. After each incubation step, wells were washed with
washing buffer (25mMTRIZMA, 50mMNaCl, 0.036%BronidoxL5,
0.1% Tween 20) using a standardized ELISA plate washing machine
(BioTek Instruments, Microplate washer, ELx405 Select CW,
Winooski, VT). An ELISA reader (VersaMAX; Molecular Devices,
Wokingham Berkshire, UK) was used to read optical densities at 450
and 650 nm. A standard curve was plotted using a 4-parametric
mathematical fit model.
Statistical analysis
All data were considered nonparametric. Categorical data from the
IFX vs the ADA cohort and from responders vs nonresponders were
compared using a Pearson x2 test or Fisher exact test where needed,
whereas continuous data were compared using a Mann-Whitney U
test (Tables 2 and 3). Differences between responders and nonre-
sponders in CRP, marker levels, and ratios were compared using a
Mann-Whitney U test with post hoc Bonferroni correction for mul-
tiple comparisons. Longitudinal differences between marker levels/
ratios frombaseline vsweek xwere compared using the Friedman test
with the post hocWilcoxon signed-rank test with Bonferroni correc-
tion for multiple comparisons. Marker levels are presented as mean
andSEof themean. Spearman rank correlation coefficientwasused to
determine correlation between the markers/ratios and HBI/CRP (see
Tables 1 and 2, Supplementary Digital Content 1, http://links.lww.
com/CTG/A372). Receiver operating characteristic curves were cal-
culated using MedCalc for Windows (MedCalc Software, Ostend,
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Belgium, version 14.8.1) for markers, which were different between
responders and nonresponses.Optimal cutoff concentrations for each
cohort were determined byMedCalc aiming at a combination of high
sensitivity and specificity. Cutoff concentrations were used to de-
termineodds ratios (ORs,with95%confidence interval [95%CI]) and
sensitivity/specificity using Fisher exact contingency analysis.
GraphPad Prism version 6.0 (La Jolla, CA) was used to design
figures and for Fisher exact contingency analysis. Analysis of
patient characteristics and markers compared with CRP/HBI
was performed using Statistical Package for Social Sciences
23.0 (SPSS, Chicago, IL). P values of ,0.05 were considered
significant.
Ethical considerations
All patients from the Aarhus cohort provided written informed con-
sent, and the study protocol was approved by the Central Denmark
Region Committees on Biomedical Research Ethics {journal no.
20080092, journal no. 20060197 [registered at ClinicalTrials.gov
(NCT00955123)], and journal no. 20040150}. All patients from the
Groningen cohort gavewritten informedconsent for theuseof patient
data and serum (approved by the Institutional Review BoardUMCG,
IRB no. 08/279) from the UMCG IBD database and biobank.
RESULTS
Cohort characteristics
Twenty-one patients were included in the IFX cohort, and 21
patients were included in theADA cohort. At baseline, patients in
the IFX cohort used significantly more systemic steroids com-
pared with the patients in the ADA cohort (Table 1). A trend for
more female patients and for patients with ileal disease in the IFX
cohort in contrast tomoremale patients and patients with colonic
disease in the ADA cohort was observed (Table 1). Baseline
biomarker levels were equal between IFX and ADA for CRP,
C3M/PRO-C3, and C4M/PRO-C4. Baseline levels of PRO-C3
(11.46 1.1 vs 16.16 0.8, P5 0.001), C3M (12.26 1.1 vs 17.46
2.2, P5 0.04), PRO-C4 (274.16 36.3 vs 510.56 99.6, P5 0.04),
and C4M (25.86 2.4 vs 38.86 2.9, P5 0.001) were higher in the
ADA cohort compared with the IFX cohort. Seventeen patients
(81%) responded in the IFX cohort, and 15 patients (71%)
responded in the ADA cohort (see Tables 1 and 2, Supplementary
Digital Content 1, http://links.lww.com/CTG/A372). No differ-
ences in baseline characteristics were observed between re-
sponders and nonresponders in the IFX or the ADA cohort.
Especially, steroid use was not different between responders and
nonresponders in the IFX cohort or the ADA cohort.
Degradation fragments of type III and type IV collagens are
elevated in anti-TNF nonresponders
Increased C4M and PRO-C4 concentrations at baseline were
observed in the IFX and in the ADA cohort in nonresponders
compared with responders. Type IV collagen formation marker
C4M was increased in nonresponders in both cohorts compared
with responders (IFX: 35.0 6 2.4 vs 23.2 6 2.6, P 5 0.04, ADA:
53.06 3.2 vs 34.16 2.8, P5 0.006). Baseline levels of the type IV
collagen formation marker PRO-C4 were also increased in non-
responders to anti-TNF (IFX: 465.86 90.5 vs 219.46 25.3, P5
0.011, ADA: 867.46 324.2 vs 391.56 62.3, P5 0.05) compared
with responders. Baseline C3M/PRO-C3 ratios were not elevated
in nonresponders at baseline in the IFX cohort (1.96 0.8 vs 1.16
0.1, P5 0.26), whereas they were increased in nonresponders in
the ADA cohort (1.7 6 0.5 vs 0.9 6 0.1, P 5 0.013). CRP levels
were equal at baseline in both cohorts.
Anti-TNF therapy differently alters the turnover of type III and IV
collagens in responders vs nonresponders
After initiation of therapy, levels of PRO-C4 remained increased
in nonresponders to anti-TNF in both the IFX (466.06 121.5 vs
257.16 24.2, P5 0.05 [Figure 2]) and the ADA cohort at weeks 6
and 8, respectively (472.6 6 63.2 vs 288.3 6 39.7, P 5 0.03
Table 1. Demographics separated by cohort
IFX (N 5 21) ADA (N 5 21) P value
Sex, n (%)
Female 17 (81.0) 10 (47.6) 0.05a










6.5 (0.3–28.4) 5.5 (0.1–12.2) 0.54b
Age at diagnosis, n (%) 0.45c
A1 (,16) 0 (0) 0 (0)
A2 (17–40) 18 (85.7) 15 (71.4)




L1 ileum (1L4) 3 (14.3) 1 2
(9.5)
2 (9.5)
L2 colon (1L4) 3 (14.3) 11
(4.8)
8 (38.1)
L3 ileocolon (1L4) 11 (52.4) 1 1
(4.8)
7 (33.3) 1 4
(19.0)
Disease behavior




18 (85.7) 19 (90.5)
Stricturing 3 (14.3) 2 (9.5)
Penetrating 0 (0) 0 (0)
Perianal disease 6 (28.6) 4 (19.0) 0.73a
Anti–TNF naive 16 (76.2)
Smoking 0.10c
Current 6 (28.6) 7 (33.3)
Used to smoke 9 (42.9) 3 (14.3)
Never 6 (28.6) 11 (52.4)
Medication when starting Anti-
TNF
Mesalazine 1 (4.8) 0 (0) .0.99c
Steroids (systemic) 7 (33.3) 0 (0) 0.01a
Immunosuppressives 17 (81.0) 12 (57.1) 0.18a
ADA, adalimumab; IFX, infliximab; TNF, tumor necrosis factor.
aFisher exact test.
bIndependent sample t test.
cx2 test.
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[Figure 3]) comparedwith responders. C4M levels were increased
in nonresponders at week 2 in the IFX cohort (29.36 2.5 vs 21.8
6 2.1, P5 0.01) and at week 8 in the ADA cohort (42.26 4.4 vs
27.9 6 2.1, P 5 0.01). In line with this, C3M levels remained
increased in nonresponders in the IFX (16.66 3.5 vs 10.66 1.0,
P5 0.01) and ADA (19.06 4.1 vs 9.96 1.4, P5 0.03) cohort at
weeks 6 and 8, respectively.
Type IV collagen degradation levels at baseline predict response
to anti-TNF
In both cohorts, degradation marker C4M at baseline was able to
predict response to anti-TNF (IFX:C4M cutoff concentration: 35.2
nmol/L, OR 39 [95% CI, 2.41–523.90], P 5 0.02, sensitivity: 0.93,
specificity: 0.75; ADA:C4M cutoff concentration: 46.9 nmol/L, OR
26 [95% CI, 1.8–332.5], P5 0.01, sensitivity: 0.93, specificity: 0.67,
Table 3). In contrast, CRP levels in neither the IFX nor the ADA
cohort were able to predict response. Although not significant in
both cohorts, similar trends were observed in both cohorts for the
type IV collagen formationmarker at baseline (IFX: PRO-C4cutoff
concentration: 339.2 nmol/L, OR 18 [95% CI, 1.53–246.1], P 5
0.04, sensitivity: 0.92, specificity: 0.60; ADA: PRO-C4 cutoff con-
centration: 409.7 nmol/L,OR11.0 [95%CI, 0.98–143.80],P50.11,
Table 3).During the inductionphase,C3M levels atweeks6–8were
able to predict response to anti-TNF in both cohorts (IFX C3M
cutoff value: 14.0 nmol/L, OR: 14.00 [95% CI, 1.38–190.60], P 5
0.05, sensitivity: 0.93, specificity: 0.50; ADA C3M cutoff concen-
tration: 14.1 nmol/L, OR: 14.7 [95% CI, 1.2–191.1], P 5 0.04,
sensitivity: 0.92, specificity: 0.57, Table 4).
Markers correlate with CRP but not with HBI
Both the IFX and in the ADA cohort, no correlation was found
between theHBI vsmarkers, their ratios, andCRP (see Tables 1 and
2, Supplementary Digital Content 1, http://links.lww.com/CTG/
A372). Negative correlation was found between CRP and PRO-C3
in the IFX cohort at week 14 (r:20.60, P5 0.01) and in the ADA
cohort atweek 8 (r:20.52,P50.03). Furthermore, (nonsignificant)
correlationwas found in betweenCRPandPRO-C4 in both cohorts
(IFX: r:20.79, P, 0.001; ADA: r:20.054, P5 0.8).
DISCUSSION
In the present pilot study, we show that serological biomarkers for
degradation of type IV collagen at baseline could identify patients
with active CD who will respond to anti-TNF therapy. MMP-2–,
MMP-9–, and MMP-12–degraded type IV collagen (C4M) levels
measured at baseline could predict response to anti-TNF in both
IFX- and ADA-treated patients. Furthermore, MMP-9–degraded
C3M levels measured during the induction phase (weeks 6–8)
could predict response to anti-TNF. These results were be
Figure 1. Inclusion flowchart of patients in the IFX and ADA cohorts. ADA, adalimumab; IFX, infliximab.
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reproduced in 2 independent cohorts of 2 different ant-TNF
treatments in which patient characteristics and response based on
reproducible HBI scores were well defined (28). Because of small
sample sizes and differences between the cohorts, predictive values
are based on different cutoff values within each cohort and there-
fore need further validation.
None of themarkers that are currently used in clinical practice
to monitor inflammation are direct derivates of tissue
Table 2. Demographics separated by response








(N 5 15) P value
Sex, n (%)
Female 3 (75.0) 14 (82.4) .0.99a 3 (50.0) 7 (46.7) .0.99a
Age at anti-TNF, yr, mean
(minimum–maximum)
35.7 (25.4–52.9) 38.2 (22.6–66.1) 0.75b 32.9 (20.1–58.9) 40.7 (21.5–67.9) 0.31b
Disease duration anti-TNF, yr,
mean (minimum–maximum)
8.3 (0.3–28.4) 6.1 (0.5–16.4) 0.59b 4.08 (0.5–9.4) 6.0 (0.1–12.2) 0.37b
Age at diagnosis, n (%)
A1 (,16) 0 (0) 0 (0) .0.99c 0 (0) 0 (0) 0.62c
A2 (17–40) 4 (100.0) 14 (82.4) 5 (83.3) 10 (66.7)
A3 (.40) 0 (0) 3 (17.60) 1 (16.7) 5 (33.3)
Disease location anti-TNF, n (%) 0.77c
Ileal (L1)1 upper GI (L4) 0 (0) 1 0 (0) 3 (17.6) 1 2 (11.8) 0.77c 0 (0) 1 0 (0) 2 (13.3) 1 0 (0)
Colonic (L2) 1 upper GI (L4) 1 (25.0) 1 0 (0) 2 (11.8) 1 1 (5.9) 3 (50.0) 1 0 (0) 5 (33.3) 1 0 (0)
Ileocolonic (L3) 1 upper GI (L4) 3 (75.0) 1 0 (0) 8 (47.1) 1 1 (5.9) 2 (33.3) 1 1 (16.7) 5 (33.3) 1 3 (20)
Disease behavior anti-TNF, n (%) 0.07c
Nonstricturing/nonpenetrating (B1) 4 (100.0) 14 (82.4) .0.99c 4 (66.7) 15 (100.0)
Stricturing (B2) 0 (0) 3 (17.6) 2 (33.3) 0 (0.0)
Penetrating (B3) 0 (0) 0 (0) 0 (0) 0 (0)
Surgery NA
Resection before anti-TNF, n (%) 1 (25.0) 3 (17.6) .0.99a 0 (0) 0 (0)
Cause of resection before
starting anti-TNF
Persistent inflammation 2 (50.0) 3 (17.6) 0.23c NA NA
Stenosis 0 (0) 0 (0)
Intra/abdominal fistula/ abscess/
perforation (with stenosis)
0 (0) 0 (0)
Perianal disease 1 (25.0) 5 (29.4) .0.99a 1 (16.7) 3 (20.0) .0.99a
Anti–TNF naive 1 (25) 15 (88.2) 0.28a 3 (50) 7 (46.7) .0.99a
Smoking
Current 0 (0) 6 (35.3) 0.32c 0.97c
Used to smoke 2 (50) 7 (41.2) 1 (16.7) 2 (13.3)
Never 2 (50) 4 (23.5) 3 (50) 8 (53.3)
Medication when starting anti-TNF
Mesalazine 0 (0) 1 (5.9) .0.99a 0 (0) 0 (0) NA
Steroids 1 (25) 6 (35.3) .0.99a 0 (0) 0 (0) NA
Immunosuppressives 3 (75) 14 (82.4) .0.99a 3 (50) 9 (60) .0.99a
ADA, adalimumab; IFX, infliximab; NA, nonapplicable; TNF, tumor necrosis factor.
aFisher exact test.
bIndependent sample t test.
cx2 test.
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inflammation. CRP is the most commonly used inflammatory
marker; however, CRP is produced and secreted by hepatocytes
during inflammation on stimulation by IL-1 and IL-6 and byTNF
originating from the site of inflammation (14). In contrast, se-
rological markers for posttranslational modification of the ECM
(both formation and degradation) are produced and released by
the disease-affected tissue directly (29). As shown in this study,
biomarkers that reflect posttranslational modifications of the
ECM can be used to predict response to anti-TNF. Since CRP has
been extensively validated as a biomarker of active inflammation
for patients with CD, the combination of CRP and serological
markers for formation and degradation of type IV collagenmight
be optimal for clinical use and in prediction of response to anti-
TNF in patients with CD.
Serological markers that indicate collagen degradation are pro-
duced by MMP-mediated cleavage of collagens at the site of in-
flammation. The antibodies used in these assays recognize the
MMP-cleaved neoepitope specifically. For C4M, the neoepitope is
cleaved off by MMP-2, MMP-9, and MMP-12. For C3M, the neo-
epitope is cleaved off by MMP-9. MMP-9 protein activity is upre-
gulated in inflamed IBD mucosa compared with noninflamed IBD
and control mucosa (16,30). Mucosal MMP expression in response
to IFXwas previously investigated byDi Sabatino et al. They showed
that mucosal MMP-3, MMP-12 mRNA, and protein expression
decreased after treatment inpatientswithCDwho responded to IFX.
Furthermore, they showed that no change in MMP expression was
found in nonresponders and that downregulation of MMP-3 and
MMP-12 correlates with improvement of the histology score (31).
Table 3. Contingency analysis at baseline
IFX ADA
Cutoff OR1 95% CI P Sensitivity Specificity Cutoff OR1 95% CI P Sensitivity Specificity
C3M 13.0 nmol/L 7.5 (0.8–105.0) 0.25 16.0 nmol/L 8.0 (0.8–105.7) 0.13
PRO-C3 16.0 nmol/L 0 (0–4.5) .0.99 16.0 nmol/L 0.4 (0.03–3.9) 0.61
C3M/PRO-C3 1.6 6 (0.6–51.0) 0.20 0.8 nmol/L 14.7 (1.2–191.1) 0.04 0.9167 0.57
C4M 35.2 nmol/L 39 (2.4–523.9) 0.02 0.93 0.75 46.9 nmol/L 26.0 (1.8–332.5) 0.01 0.9286 0.67
PRO-C4 339.2 nmol/L 18 (1.5–246.1) 0.04 0.92 0.60 409.7 nmol/L 11.0 (1.0–143.8) 0.11
C4M/PRO-C4 0.1 3 (0.4–43.8) 0.59 0.1 nmol/L 0.9 (0.1–6.8) .0.99
ADA, adalimumab; CI, confidence interval; IFX, infliximab; OR, odds ratio.
Figure 2. Serum biomarker levels and ratios responders (blue) vs nonresponders (red) to anti-TNF in the IFX cohort. Asterisks indicate the level of
significance, *P, 0.05 at different time points comparedwith the baseline. Hashtags (#) indicate the level of significance #P, 0.05, ##P, 0.01 between
responders and nonresponders at a given time point. Parentheses with a hashtag (#) indicate non-Bonferroni-corrected significant differences between
responders and nonresponders at a given time point. Marker levels are presented asmean and SE of themean. IFX, infliximab; TNF, tumor necrosis factor.
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Another study showed that serum levels ofMMP-9 decrease on IFX
induction treatment in patients with active luminal CDor fistulizing
CD and observed a trend for lowerMMP-9 levels at weeks 6 and 10
in responders to IFX (32). These data are in line with the decreasing
concentrationsofMMP-cleaveddegradationproducts of collagen III
and IVmeasured in responders in this study. De Bruyn et al. (33,34)
showed thatMMP-9 is a surrogatemarker to assessmucosal healing
in CD. These results are in line with the decreased C3M levels (a
surrogate marker for MMP-9 activity) in responders in the IFX and
ADA cohort in our study.
Our results show that responders could be differentiated from
nonresponders, based on levels of degradation markers of type IV
collagen (C4M), already at baseline, before anti-TNF therapy was
administered. Baseline PRO-C4 concentrations were different be-
tween responders and nonresponders in both cohorts, but the pre-
diction model was only statistically significant in the IFX cohort.
Figure3.Serumbiomarker levels and ratios responders (blue) vsnonresponders (red) to anti-TNF in theADAcohort. Asterisks indicate the level of significance,
*P, 0.05 at different time points comparedwith the baseline. Hashtags (#) indicate the level of significance #P, 0.05, ##P, 0.01 between responders and
nonresponders at a given time point. Parentheses with a hashtag (#) indicate non-Bonferroni-corrected significant differences between responders and
nonresponders at a given time point. Marker levels are presented as mean and SE of the mean. ADA, adalimumab; TNF, tumor necrosis factor.
Table 4. Contingency analysis during anti-TNF induction therapy
IFX ADA
Cutoff OR1 95% CI P Sensitivity Specificity Cutoff value OR 1 95% CI P Sensitivity Specificity




0.05 0.93 0.50 14.13 nmol/L 14.67 (1.17–191.10) 0.04 0.92 0.57
C3M/PRO-C3wk 2 1.3 nmol/L Infinity (2.974-
Infinity)
0.02 0.94 1.00
C3M/PRO-C3wk 8 1.1 nmol/L 21.00 (1.80–284.10) 0.03 0.88 0.75
PRO-C4 wk 1 334.52
nmol/L
7.50 (0.88–96.42) 0.15
C4M wk 6 (IFX),
wk 8 (ADA)










19.50 (1.67–265.10) 0.04 0.87 0.75
ADA, adalimumab; CI, confidence interval; IFX, infliximab; OR, odds ratio.
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Nonfibrillar type IV collagen is, as everywhere in the body, the main
component of the basement membrane forming the barrier between
the epithelium on the intestinal luminal side and the lamina propria
of the intestine (35). Serum concentrations of collagen IV are de-
creased in patients with IBD as previously reported by Koutroubakis
et al. (36) They suggest altered type IV collagen metabolism in pa-
tients with IBD, but do not clarify whether a decrease in circulating
type IV collagen corresponds to a decrease in serum formation or
degradation products of type IV collagen. Our results show increased
serum levels of formation and degradation products of type IV col-
lagen in nonresponders compared with responders, indicating in-
creased turnover of type IV collagen in nonresponders. Increased
turnover of type IV collagenmight reflect a decrease in the amount of
type IV collagen that is deposited in the basement membrane of the
affected intestine and may indicate a more severe disease phenotype
in which themucosa is severely affected. Intestinal barrier function is
impaired in patients with CD compared with healthy controls (37).
An important role forTNF in intestinalhomeostasis, barrier function,
and pathogenesis has been suggested (38). The role of anti-TNF was
confirmed in studies that showed that intestinal permeability nor-
malizes following successful anti-TNF (IFX) therapy in patients with
active CD (39). Our data indicate that an increase in type IV collagen
turnover in nonresponders (and therefore a decrease in net deposited
type IV collagen) is associated with nonresponse to anti-TNF, per-
haps due to a decrease in deposited type IV collagen leading to im-
paired intestinal barrier function (36). Nonresponse to anti-TNF
might be explained by the inability of the intestine to restore the
intestinal basementmembrane,whichpredominantly consists of type
IV collagen, and thereby the inability to restore its barrier.
As C4M formation and degradation markers are not drug specific
butmight reflect the state of the intestinal barrier (andwhether an anti-
inflammatory drug is able to restore this), these markers may be suit-
able tomonitor response tootherbiologicals (within the anti-TNFclass
or to another biological (e.g., anti-IL12/23, JAK/STAT inhibitors, anti-
a4b7, sphingosine-1-phosphate inhibitors, and anti–MAdCAM-1) in
patients with CD or Ulcerative colitis (UC) as well. Further studies
might show that patients with high C4M at baseline could better be
treatedwith, e.g., anti-IL12/23comparedwithanti-TNFor thatpatients
havingaC4Mserumlevelaboveacertain thresholdarepredicted tonot
respond to biologicals and are better offered an ileocecal resection.
Our results furthermore show that response to anti-TNF can
be predicted based on serum levels of MMP-9–degraded C3M at
weeks 6–8 after the start of therapy. Increased C3M concentra-
tions in nonresponders to anti-TNF indicate less suppression of
MMP-9 activity on induction therapy and thereby less suppres-
sion of tissue inflammation compared with responders. This is in
line with C4M serum concentrations measured in responders vs
nonresponders. These results (C3M and C4M) further confirm
that tissue inflammation (i.e., MMP activity) is reduced on anti-
TNF therapy and that the degree of reduction of tissue in-
flammation is indicative of response to anti-TNF. Based on serum
concentrations of biomarkers for interstitial C3M determined
during the anti-TNF induction phase, one cannot conclude
whether anti-TNF is pro- or anti-fibrotic on the long term.
Measuring markers reflecting formation and degradation of in-
terstitial collagen (type I and III collagens) in a cohort of patients
with CD in remission might be suitable to answering this ques-
tion. Ideally, concentrations of formation and degradation
markers of interstitial collagens would be correlated (and thereby
validated) to quantification of fibrosis by imaging (by ultrasound,
computed tomography enterography, or magnetic resonance
enterography). Unfortunately, intestinal fibrosis cannot be ade-
quately quantified by imaging so far (40).
Furthermore, the predictive value of the delta between base-
line biomarker levels and biomarker levels measured during the
induction phase was inferior to the predictive value of the abso-
lute biomarker concentrations. Therefore, ORs calculated from
absolute biomarker concentrations are shown.
A major limitation of this study is its sample size. Although the
results observed in the IFX cohort could be reproduced in a com-
parable ADA cohort, these cohorts would ideally have been larger.
Patients with different disease location (ileal, colonic, or ileocolonic)
and disease behavior (nonstricturing/nonpenetrating [majority],
stricturing [9.5%–14.3%]) were combined in this pilot study, causing
variation. We have previously observed differences in serological
biomarkers of ECM formation and degradation between
nonstricturing/nonpenetrating, stricturing, and penetrating disease
in patients with solely ileal disease (16). The surface area of the in-
flammation-affected region presumably correlates with biomarker
levels (especially levels of the byMMP-activity formed neoepitopes).
Ideally, onewould validate thepredicting value of these biomarkers in
response to anti-TNF for each of the phenotypeswithin theMontreal
classification (behavior and location) in a larger cohort. Because the
sample sizes of both cohorts were small, high variation in marker
levels between the 2 cohorts was observed. Differences in baseline
biomarker concentrations between the cohorts lead to differences in
cutoff concentrations (used to determine sensitivity and specificity)
between the 2 cohorts, as thesewere calculatedper cohort permarker.
This variation might be explained by the difference in steroid use at
baseline between the 2 cohorts. Furthermore, this study focused on
the 2 for CD most widely used anti-TNF therapies. These results
should be separately validated for other anti-TNF therapies (certoli-
zumab, etanercept, and golimumab) used for IBD and other (rheu-
matic) diseases. The generalizability of this study remains therefore to
be validated. Also, correlation to endoscopic mucosal healing, fecal
calprotectin, imaging, histology of the basement membrane in bi-
opsies from endoscopy, and response profiles for each of the disease
phenotypes (inflammatory, stricturing, and penetrating CD) are
needed before these biomarkers can be used in clinical practice. This
pilot study intended tobe aproof of concept showing that biomarkers
of ECM turnover can predict response to anti-TNF and was not
intended to define final reference concentrations.
Furthermore, in this retrospective cohort study, endoscopic data
were not available because colonoscopy was not routinely per-
formed after remission induction with IFX/ADA. Only from a few
patients, fecal calprotectin levels were available after remission in-
duction with anti-TNF. In prospective studies validating these
markers as markers for mucosal healing, correlation to the simple
endoscopic score for CD and fecal calprotectin is needed. It is
known that the simple endoscopic score–CD correlates closest with
fecal calprotectin, followed by CRP, blood leukocytes, and the
Crohn’s Disease Activity Index (CDAI) (41). These data were,
however, not available in this pilot study.
Next to this, this study included patients who receivedADAor
IFX for at least 14 weeks. Hereby, we did not include primary
nonresponders who ended treatment before week 14. Ideally, this
subgroup would be included, and a biomarker would be valid to
discriminate between all subgroups, namely primary nonre-
sponders, nonresponders at weeks 8–14, and responders.
Furthermore, this study lacks the correlation and correction of
biomarker levels and IFX/ADAdrug concentrations in plasma. This
might explain part of the observed variation. Determining trough
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levels andantibodies against IFX/ADAwasnot considerednecessary
in the patients included in this studywithin thefirst 14weeks of anti-
TNF treatment as patients had sufficient clinical response. The
probability that patients developed antibodies to IFX within the first
14 weeks is small (42). However, we cannot exclude that responders
had higher drug levels compared with nonresponders.
In summary, we are the first to show that clinical response to
anti-TNF for patients with active CD can be predicted at baseline
based on a serological marker for MMP-degraded type IV col-
lagen (C4M) at baseline and based on MMP-9–degraded C3M
measured during the induction phase (weeks 6–8). The results of
this study are promising but need validation.
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